TG Therapeutics is a biopharmaceutical company that develops and commercializes treatments for B-cell diseases and multiple sclerosis, including its anti-CD20 therapy.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Larry Robbins / Glenview | 61 | New buy | 4,800 | $267,744 | 0.0% |
| Bridgewater | 55 | Added +36% | 586,631 | $32,722,277 | 0.1% |
| Steve Cohen / Point72 | 75 | Added +53% | 560,269 | $31,251,805 | 0.0% |
| Ancora | 42 | Trimmed -17% | 250 | $13,945 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-09-22 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-05-14 | Trump, Donald J President | SELL | $15.001 - $50,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $50,001 - $100,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.